Minimally invasive image-guided therapy of primary and metastatic pancreatic cancer
| Autor: | András Bibok, Mokenge P. Malafa, Dae Won Kim, Bela Kis |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Ablation Techniques
Oncology medicine.medical_specialty medicine.medical_treatment Review Malignancy Cryosurgery Metastasis Pancreatic tumor Pancreatic cancer Internal medicine medicine Humans Interventional radiology Radiofrequency Ablation medicine.diagnostic_test business.industry Liver Neoplasms Microwave ablation Gastroenterology Therapeutic embolization General Medicine Irreversible electroporation medicine.disease Pancreatic Neoplasms Radiation therapy Electroporation business |
| Zdroj: | World Journal of Gastroenterology |
| ISSN: | 1007-9327 |
| DOI: | 10.3748/wjg.v27.i27.4322 |
| Popis: | Pancreatic cancer is a challenging malignancy with limited treatment options and poor life expectancy. The only curative option is surgical resection, but only 15%-20% of patients are resectable at presentation because more than 50% of patients has distant metastasis at diagnosis and the rest of them has locally advanced pancreatic cancer (LAPC). The standard of care first line treatment for LAPC patients is chemotherapy with or without radiation therapy. Recent developments in minimally invasive ablative techniques may add to the treatment armamentarium of LAPC. There are increasing number of studies evaluating these novel ablative techniques, including radiofrequency ablation, microwave ablation, cryoablation and irreversible electroporation. Most studies which included pancreatic tumor ablation, demonstrated improved overall survival in LAPC patients. However, the exact protocols are yet to set up to which stage of the treatment algorithm ablative techniques can be added and in what kind of treatment combinations. Patients with metastatic pancreatic cancer has dismal prognosis with 5-year survival is only 3%. The most common metastatic site is the liver as 90% of pancreatic cancer patients develop liver metastasis. Chemotherapy is the primary treatment option for patients with metastatic pancreatic cancer. However, when the tumor is not responding to chemotherapy or severe drug toxicity develops, locoregional liver-directed therapies can provide an opportunity to control intrahepatic disease progression and improve survival in selected patients. During the last decade new therapeutic options arose with the advancement of minimally invasive technologies to treat pancreatic cancer patients. These new therapies have been a topic of increasing interest due to the severe prognostic implications of locally advanced and metastatic pancreatic cancer and the low comorbid risk of these procedures. This review summarizes new ablative options for patients with LAPC and percutaneous liver-directed therapies for patients with liver-dominant metastatic disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|